Other News

Abiomed Announces Q3 FY 2020 Revenue of $222 Million and 31.7% Operating Margin

DANVERS, Mass.–(BUSINESS WIRE)–Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart recovery and support technologies, today reported third quarter fiscal 2020 revenue of $221.6 million, an increase of 10% compared to revenue of $200.6 million for the same period of fiscal 2019. Operating income was $70.3 million, up 13%, compared […]

Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Recent Period Activity

− Achieved Fourth Quarter and Full Year 2019 ONPATTRO® (patisiran) Global Net Product Revenues of $55.8 Million and $166.4 Million, Respectively – − As of Year-End 2019, Over 750 Patients Worldwide Receiving Commercial ONPATTRO, with Over 1,000 Total Patients Worldwide Being Treated with Patisiran – – Observed Strong Initial Demand for […]

BioVentrix Receives 2020 NUB Reimbursement Status 1 Renewal in Germany for the Revivent TC TransCatheter Ventricular Enhancement System

SAN RAMON, Calif.–(BUSINESS WIRE)–BioVentrix, Inc., developer of the first transcatheter device for left ventricular remodeling after a heart attack, today announced it received renewal of the highest priority reimbursement in Germany for the Revivent TC™ TransCatheter Ventricular Enhancement System by achieving the NUB Status 1 designation from InEk, the German […]

Bristol-Myers Squibb Reports Fourth Quarter and Full Year Financial Results for 2019

NEW YORK–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) today reports results for the fourth quarter and full year of 2019, which highlight continued strong sales and robust operating performance, along with the ongoing advancement of the company’s pipeline. “By all measures, 2019 was a transformative year for Bristol-Myers Squibb as we progressed our […]

AngioDynamics Appoints Stephen Trowbridge Executive Vice President and Chief Financial Officer

LATHAM, N.Y.–(BUSINESS WIRE)–AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it has appointed Stephen Trowbridge to the role of Executive Vice President and Chief Financial Officer, effective February 5, 2020. Mr. Trowbridge has served […]

Enrollment of the VasQ™ External Support US Pivotal Study Now Complete

TEL AVIV, Israel, Feb. 4, 2020 /PRNewswire/ — Laminate Medical Technologies (Laminate) has announced the completion of enrollment into the VasQ™ External Support US Pivotal Study.  The study was conducted at 17 sites across the U.S. and prospectively enrolled 144 male and female patients in need of an arteriovenous fistula (AVF) for […]

Itamar™ Medical Announces Closing of Upsized Public Offering of American Depositary Shares and Full Exercise of the Underwriters’ Option to Purchase Additional ADSs

CAESAREA, Israel, Feb. 04, 2020 (GLOBE NEWSWIRE) — Itamar Medical Ltd. (Nasdaq: ITMR) (TASE: ITMR), a medical technology company focused on the development and commercialization of non-invasive medical devices to aid in the diagnosis of respiratory sleep disorders, today announced the closing of its upsized public offering of 2,927,267 American […]

Paragonix Technologies, Inc., Announces First Successful Use of Paragonix SherpaPak™ Cardiac Transport System in Pediatric Transplant Recipients

Paragonix SherpaPak™ Cardiac Transport System is the only FDA-cleared and CE-marked device that safeguards hearts between donor and recipient patients CAMBRIDGE, Mass.–(BUSINESS WIRE)–Paragonix Technologies, Inc. today announced that the first series of pediatric donor hearts preserved and transported using Paragonix SherpaPak Cardiac Transport System occurred at University of Florida Health (UF […]

Inositec’s INS-3001 Significantly Reduces Cardiovascular Calcification in Proof-of-Concept Studies Published in Nature Communications

ZURICH–(BUSINESS WIRE)–Inositec, a pioneer in the development of life-saving small molecule drugs based on myo-inositol hexaphosphate (IP6), announced today that positive proof-of-concept data on INS-3001, a novel cardiovascular calcification inhibitor, were published in Nature Communications (DOI: 10.1038/s41467-019-14091-4). INS-3001 was found to be a potent and well tolerated inhibitor of pathological soft tissue calcification […]